Company Filing History:
Years Active: 2021
Title: **Alexander Henrik Baron Van Asbeck: Innovator in Nanotechnology**
Introduction
Alexander Henrik Baron Van Asbeck is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of nanotechnology, particularly with his innovative patent that focuses on biodegradable particles. His work aims to advance medical applications and improve therapeutic delivery systems.
Latest Patents
Alexander holds a patent for a unique nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer, and an acylated human lactoferrin-derived peptide. The core of this nanoparticle includes a combination of a bio-resorbable polyester and a hydrophilic polymer, either as a part of the bio-resorbable polyester or as a separate entity. The acylated human lactoferrin-derived peptide, which has the amino acid sequence SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR, is coated onto this core. Importantly, this peptide sequence can vary up to eight amino acid positions, while its N-terminus is acylated with a C-monoacyl group, enhancing its functionality in biomedical applications.
Career Highlights
Alexander is currently associated with Evonik Operations GmbH, a company renowned for its innovative materials and solutions. His role at Evonik has allowed him to explore groundbreaking technologies in the field of nanoparticles and their applications. His research continues to push the boundaries of science and engineering, focusing on the integration of biology and materials science.
Collaborations
Throughout his career, Alexander has collaborated with esteemed colleagues such as Roland Brock and Rike Nabbefeld. These collaborations demonstrate his commitment to working alongside other experts in order to enhance the impact of their collective research on innovations in nanotechnology.
Conclusion
Alexander Henrik Baron Van Asbeck's contributions to nanotechnology through his patent on biodegradable nanoparticles illustrate the vital link between innovation and medical application. As he continues to work at Evonik Operations GmbH and collaborates with other experts in the field, his endeavors stand to significantly impact future advancements in therapeutic delivery and beyond.